Year: 2019

Ilkka-Yhtymä Oyj                  Pörssitiedote 18.11.2019, klo 8.40

MOSCOW and AMSTERDAM, the Netherlands, Nov. 18, 2019 (GLOBE NEWSWIRE) — Yandex (NASDAQ and MOEX: YNDX), one of Europe’s largest internet companies and the leading search provider in Russia, today announces that its Board of Directors has approved targeted amendments to the company’s corporate governance structure, as it seeks to respond to an evolving regulatory environment while supporting the company’s business interests and the interests of all its stakeholders.The proposed amendments will be subject to shareholder approval at a Meeting of Class A Shareholders and an Extraordinary General Meeting of Shareholders, both scheduled to take place on December 20, 2019.“I am pleased to endorse the proposed amendments,” said John Boynton, Chairman of the Board of Yandex. “They are good for Yandex and good for our shareholders.”“It...

Company announcement no 2019-14                      18 November 2019Interim Management Statement covering the period year-to-dateRecovery in hearing aid wholesale is progressing as planned and growth momentum is building upHearing aid retail business has normalised during NovemberContinued strong momentum in Hearing Implants and Diagnostics – both unaffected by IT incidentMaintaining outlook for EBIT of DKK 2.0-2.3bn, we expect share buy-backs of DKK 1.0bn in 2019Overall, the Group has seen solid growth year-to-date despite a significant, negative impact from the IT incident in September. Growth has been driven by modest organic growth in combination with positive contributions from both acquisitions and exchange rates.As previously communicated, the Group’s IT infrastructure was hit by cybercrime on 3 September 2019. A ransomware intrusion...

Selskabsmeddelelse nr. 2019-14                                     18. november 2019Periodemeddelelse for perioden år til datoGenetablering af engrossalg af høreapparater i fremdrift som planlagt, og vækstmomentum øgesNormalisering af forretningen for detailsalg af høreapparater i løbet af novemberFortsat stærkt momentum i Høreimplantater og Diagnostik – begge upåvirket af it-hændelsenFastholder forventning om EBIT på DKK 2,0-2,3 mia., forventer aktietilbagekøb på DKK 1,0 mia. i 2019Koncernen har samlet set oplevet solid vækst år til dato på trods af en betydelig negativ effekt af it-hændelsen i september. Væksten har været drevet af beskeden organisk vækst samt positive bidrag fra både akkvisitioner og valutakurser.Som tidligere meddelt blev koncernens it-infrastruktur ramt af cyberkriminalitet den 3. september 2019. En ransomware-indtrængen...

Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancerFollow-up data from pivotal phase III APHINITY study evaluating Perjeta plus Herceptin and chemotherapy in HER2-positive early breast cancerResults from phase III FeDeriCa study confirming the non-inferiority of a fixed-dose combination of Perjeta and Herceptin administered under the skin             Basel, 18 November – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies from across its growing breast cancer portfolio will be presented at the San Antonio Breast Cancer Symposium (SABCS), from 10-14 December 2019. These data include new results in HER2-positive breast cancer and studies of new molecules in hormone receptor-positive (HR-positive) breast cancer.Overview of Roche studies to...

Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Plans

Valneva publie d’excellents résultats finaux de Phase 1 pour son candidat vaccin contre le chikungunyaLes résultats de Phase 1 obtenus dans les différents groupes vaccinés jusqu’au 13ème mois confirment un excellent profil d’immunogénicité et d’innocuité pour le candidat vaccin à injection unique de Valneva, VLA1553Le Groupe prévoit d’accélérer le développement du programme et d’entrer en essai pivot de Phase 3 en 2020 (sous réserve de l’accord de la FDA)Etudes complémentaires en bonne voie pour plaider en faveur d’une fin de Phase 2Profil d’immunogénicité excellent et durable dans tous les groupes vaccinésTaux de séroconversion de 100% atteint au 14ème jour après une seule injection du vaccinCe taux demeure à 100% après 12 mois sans déclin des titres d’anticorps neutralisants dans les groupes vaccinés après une seule injectionVaccin...

BEIJING, Nov. 18, 2019 (GLOBE NEWSWIRE) — Wanda Sports Group Company Limited (the “Company”, and together with its consolidated entities, “Wanda Sports”, the “Group” or “we”) (NASDAQ: WSG), a leading global sports events, media and marketing platform, today announced its unaudited financial results for the third quarter ended September 30, 2019.Third Quarter 2019 Highlights: Total revenue was €245.2 million (US$267.4 million), representing an increase of 8% year-over-year. Excluding the impact of reimbursement revenue1, total revenue was €242.5 million (US$264.5 million), a 33% increase over the third quarter of 2018.Loss for the period was €31.2 million (US$34.0 million), compared to a profit for the period of €13.1 million for the third quarter of 2018. Our performance was impacted by stock-based compensation expenses, the remaining...

Lochem, 18 November 2019Update on share buy-back programme ForFarmersForFarmers N.V. (ForFarmers) has repurchased 127,507 shares in the period from 11 November 2019 through 15 November 2019.The shares were repurchased at an average price of €5.78 per share, for a total amount of €736,933. These repurchases were made in accordance with the authorisation granted by the ForFarmers Annual General Meeting of Shareholders on 26 April 2019 as part of the share buy-back programme as announced on 3 May 2019.The total number of shares that has been repurchased to date according to this programme is 2,339,189 shares, for a total amount of €15,079,366.More information about the purchase programme is available on the ForFarmers website www.forfarmersgroup.eu/en.This press release contains information that qualifies as inside information in the sense...

Lochem, 18 november 2019Voortgang inkoopprogramma eigen aandelen ForFarmersForFarmers N.V. (ForFarmers) heeft in de periode van 11 november 2019 tot en met 15 november 2019 127.507 aandelen ingekocht.De aandelen zijn ingekocht met een gemiddelde prijs van €5,78 per aandeel, voor een totaalbedrag van €736.933. Deze inkopen zijn gedaan in overeenstemming met de machtiging verleend door de Algemene Vergadering van Aandeelhouders van ForFarmers op 26 april 2019 als onderdeel van het inkoopprogramma van eigen aandelen zoals aangekondigd op 3 mei 2019.Het totaal aantal aandelen dat tot op heden volgens dit programma is ingekocht bedraagt 2.339.189 aandelen, voor een totaalbedrag van €15.079.366.Meer informatie over het inkoopprogramma is beschikbaar op de website van ForFarmers www.forfarmersgroup.eu.Dit persbericht bevat informatie die kwalificeert...